313 related articles for article (PubMed ID: 17968973)
1. Concepts and goals in the management of transfusional iron overload.
Porter JB
Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
[TBL] [Abstract][Full Text] [Related]
2. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
[TBL] [Abstract][Full Text] [Related]
3. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
4. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
5. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.
Kwiatkowski JL; Cohen AR
Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620
[TBL] [Abstract][Full Text] [Related]
7. Iron loading and its clinical implications.
Hershko C
Am J Hematol; 2007 Dec; 82(12 Suppl):1147-8. PubMed ID: 17963253
[TBL] [Abstract][Full Text] [Related]
8. Optimizing iron chelation strategies in beta-thalassaemia major.
Porter JB
Blood Rev; 2009 Dec; 23 Suppl 1():S3-7. PubMed ID: 20116637
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
[TBL] [Abstract][Full Text] [Related]
10. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
11. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
[TBL] [Abstract][Full Text] [Related]
12. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
13. Post-transfusional iron overload in the haemoglobinopathies.
Thuret I
C R Biol; 2013 Mar; 336(3):164-72. PubMed ID: 23643400
[TBL] [Abstract][Full Text] [Related]
14. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
Ault P; Jones K
Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
[TBL] [Abstract][Full Text] [Related]
15. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
Shander A; Cappellini MD; Goodnough LT
Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Messa E; Cilloni D; Messa F; Arruga F; Roetto A; Saglio G
Acta Haematol; 2008; 120(2):70-4. PubMed ID: 18827475
[TBL] [Abstract][Full Text] [Related]
17. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.
Ho PJ; Tay L; Lindeman R; Catley L; Bowden DK
Intern Med J; 2011 Jul; 41(7):516-24. PubMed ID: 21615659
[TBL] [Abstract][Full Text] [Related]
18. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
19. Current approach to iron chelation in children.
Aydinok Y; Kattamis A; Viprakasit V
Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
[TBL] [Abstract][Full Text] [Related]
20. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey.
Vichinsky EP; Ohene-Frempong K;
Pediatr Hematol Oncol; 2011 Feb; 28(1):37-42. PubMed ID: 20673029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
